$CGON

$62.94 +$1.38 (2.24%) Close

$CGON Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 88.6M shares outstanding

Who owns CGON?

By type of holder

Institutions 100.0% Insiders 0.0% Everyone else 0.0%

Concentration Top 10 holders own 61.0%

RTW Investments, LP 9.6% · T. Rowe Price Investment Management, Inc. 7.5%

Institutional ownership

100.0%

+0.6 pts vs last qtr

Institutional holders

226

-7 vs last qtr

Net shares bought

+5.7M

by institutions in Q2 2026

New / sold out

33 / 40

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Seven Fleet Capital Management LP +1.8M
RTW Investments, LP +1.5M

Biggest sellers in Q2 2026

Driehaus Capital Management LLC SOLD OUT −999.6K
Braidwell LP SOLD OUT −984.8K

Who is planning to sell?

Notices of proposed sale, last 12 months

$64M

31 notices from 5 people

Shares covered

857.6K

0.97% of the company

Arranged in advance

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Ambaw Bellete Officer $59.4M
James Mulay Director 10b5-1 $2.31M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2023–FY2025

+1684.9%

+322.48% a year

Each share's claim on the business

−94.4%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $39.6M

over 3 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years80% Under 1 year20%

Quarterly turnover

12.6%

of institutional shares changed hands

Top 10 managers, median time held

2.3 years

Super Investors

Investment managers reporting CGON on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
RI RTW Investments, LP	8.5M	9.61%	+1.5M (+21.9%)	2024	5.2%
Shares held by quarter Peak holding8.5M (Q2'26) Change over 8 quarters+7.2M Share of the company9.610% RTW Investments, LP's full portfolio →
TR T. Rowe Price Investment Management, Inc.	6.6M	7.46%	−103.5K (−1.5%)	Q4 '25	0.3%
Shares held by quarter Peak holding6.7M (Q1'26) Change over 8 quarters+6.6M Share of the company7.460% T. Rowe Price Investment Management, Inc.'s full portfolio →

RTW Investments, LP

8.5M

% of company

9.61%

Change vs last qtr

+1.5M (+21.9%)

Held since

2024

T. Rowe Price Investment Management, Inc.

6.6M

% of company

7.46%

Change vs last qtr

−103.5K (−1.5%)

Held since

Q4 '25

28 more super investors behind a free account

See every manager holding CG Oncology, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting CGON on Form N-PORT; together they hold 41.7% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VH Vanguard Health Care Fund Vanguard Specialized Funds	$204M	2.9M	3.23%	0.53%	July 31, 2026
TR T. Rowe Price Capital Appreciation Fund T. Rowe Price Capital Appreciation Fund, Inc.	$183M	2.6M	2.90%	0.26%	June 30, 2026

Vanguard Health Care Fund

Vanguard Specialized Funds

Position value

$204M

% of company

3.23%

% of the fund

0.53%

As of

July 31, 2026

T. Rowe Price Capital Appreciation Fund

T. Rowe Price Capital Appreciation Fund, Inc.

Position value

$183M

% of company

2.90%

% of the fund

0.26%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding CG Oncology, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
JT Juliet Tammenoms Bakker 5%+ holder 13D · 6.0%	4.7M	5.26%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company5.260% Disclosed stake13D · 6.0% View the 13D/G filing →
PG Patrick G. Enright 5%+ holder 13D · 6.0%	4.7M	5.26%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company5.260% Disclosed stake13D · 6.0% View the 13D/G filing →

Juliet Tammenoms Bakker

5%+ holder13D · 6.0%

4.7M

% of company

5.26%

Change vs last qtr

—

Held since

—

Patrick G. Enright

5%+ holder13D · 6.0%

4.7M

% of company

5.26%

Change vs last qtr

—

Held since

—

8 more holders behind a free account

See every insider and 5%+ holder of CG Oncology, Inc..

Comments